Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.760
-0.060 (-2.13%)
At close: Apr 10, 2026, 4:00 PM EDT
2.800
+0.040 (1.45%)
After-hours: Apr 10, 2026, 7:42 PM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,981,003
Market Cap
11.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | 0 | - |
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BioCardia | 20 |
| Theriva Biologics | 16 |
| Soligenix | 16 |
| Genprex | 13 |
| Traws Pharma | 7 |
| Cadrenal Therapeutics | 4 |
CLRB News
- 5 weeks ago - Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences Expands Global Intellectual Property Estate - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - GlobeNewsWire
- 5 months ago - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - GlobeNewsWire
- 7 months ago - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - GlobeNewsWire